Cellceutix Corporation has reported that Kevetrin has demonstrated anti-tumour activity in the treatment of a pancreatic carcinoma cell line in a xenograft tumour model.

The three-week study showed that, in animals, the drug reduced tumour volume by 67% and delayed tumour growth by more than than 94% with no weight loss.

The company is conducting the second phase of the study, to evaluate efficacy of the drug.